As COVID-19 continues to ravage parts of the world, global industries, including tech, healthcare and pharmaceutical, are racing to overcome the speed of the virus. However, traditional, standalone R&D efforts led by the healthcare industry can be timely and costly, giving the virus what it wants--more time to spread. Some ventures are merging artificial intelligence (AI) into their efforts to find novel drug and re-purposing treatment opportunities, however, AI can only be so helpful in this ongoing fight. In order to accelerate disease treatment and address this critical demand, blending the power of AI and big data with patient biology will enable a more efficient process to discover potential drugs and enhance our understanding of potential effects on patients. This novel virus demands a novel approach, and you may ask why adding AI, an emerging, practically captivating technology, into existing efforts is not sufficient, or why it's not a one-size-fits-all solution.